Piper Sandler raises ImmunityBio price target to $16 after FDA expands bladder cancer treatment approval

Piper Sandler raised its price target for ImmunityBio from $12 to $16 following the FDA's expanded approval of ImmunityBio's ANKTIVA treatment for certain bladder cancers. This approval broadens the patient base eligible for the therapy, potentially increasing ImmunityBio's market opportunity. The stock currently trades at $9.91, implying a 61.5% upside to the new target. This development highlights ImmunityBio's growing role in innovative cancer treatments, though the exact patient uptake remains uncertain.

ImmunityBio's market cap stands at $10.50 billion as of Oct 15, 2026, 20:15 WIB, with a daily trading volume of 30,068,214 shares on Pluang. The stock price is currently $9.94, showing a modest 0.30% increase over the day. This trading activity reflects steady investor interest in ImmunityBio amid recent FDA approvals expanding its treatment indications.